Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F24%3A00080925" target="_blank" >RIV/65269705:_____/24:00080925 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/24:00138460

Result on the web

<a href="https://www.frontiersin.org/journals/oral-health/articles/10.3389/froh.2024.1473049/full" target="_blank" >https://www.frontiersin.org/journals/oral-health/articles/10.3389/froh.2024.1473049/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/froh.2024.1473049" target="_blank" >10.3389/froh.2024.1473049</a>

Result language

angličtina

Original language name

Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy

Original language description

Both denosumab (DMB) and bisphosphonates (BPs), antiresorptive drugs (ARDs) used for the treatment of osteoporosis and oncological disorders, are known for their potential to cause medication-related osteonecrosis of the jaws (MRONJ). Besides ARDs, statins were recently associated with MRONJ development, especially in patients taking higher doses of statins for a longer period of time. Here, we report a case of a female patient with osteoporosis using statins and treated with alendronate for 3 years who rapidly developed MRONJ stage III after only a single low dose of DMB. After partial maxillectomy complete healing was observed without any recurrence. We performed a literature review of cases with MRONJ triggered by a single low dose of DMB, with or without previous application of other ARDs. Only six similar cases of patients who developed MRONJ after a single low dose of DMB following previous BP therapy have been reported so far. Besides these, literature reports one patient who developed MRONJ after a single dose of DMB following romosozumab treatment and five cases developing MRONJ after a single dose of DMB even without any previous ARD treatment. We suggest that before DMB therapy is initiated, all factors predisposing to MRONJ development should be considered.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30208 - Dentistry, oral surgery and medicine

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in Oral Health

ISSN

2673-4842

e-ISSN

2673-4842

Volume of the periodical

5

Issue of the periodical within the volume

DEC 2024

Country of publishing house

CH - SWITZERLAND

Number of pages

8

Pages from-to

1473049

UT code for WoS article

001379287300001

EID of the result in the Scopus database

2-s2.0-85212301211